GL GOODLIFE SERIES BLOOD GLUCOSE MONITORING SYSMTEM
Device Facts
| Record ID | K113307 |
|---|---|
| Device Name | GL GOODLIFE SERIES BLOOD GLUCOSE MONITORING SYSMTEM |
| Applicant | Hmd Biomedical, Inc. |
| Product Code | LFR · Clinical Chemistry |
| Decision Date | Jul 27, 2012 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1345 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
The GoodLife AC-300 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-300 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients. The GoodLife AC-300 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-300 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-300 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife Glucose Control Solutions are for use with the GoodLife AC-300 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
Device Story
System measures capillary whole blood glucose via amperometric assay using glucose dehydrogenase (GDH-FAD) enzyme chemistry. User applies 0.5 μL blood sample to test strip; meter detects current proportional to glucose concentration. Used at home (single-patient models) or clinical settings (professional multiple-patient models). Professional models require single-use, auto-disabling lancing devices and disinfection between patients. Meter displays results to user/clinician to aid diabetes management. Professional models include validated disinfection protocols for multi-patient use.
Clinical Evidence
Clinical performance evaluated via lay-user study (N=150) comparing fingerstick results to YSI reference method. Results showed high correlation (R=0.97 for lay-users, R=0.99 for technicians). System accuracy met ISO 15197:2003 criteria, with 96% of results within ±20% of YSI reference values for glucose concentrations ≥75 mg/dL.
Technological Characteristics
Electrochemical biosensor; FAD-glucose dehydrogenase enzyme. Amperometric detection. Implicit coding via test strip insertion. Dimensions/form factor vary by housing model. Operating range 10-40°C. Standalone device. No PC transmission. Check strip composed of PCB, resistor, and covers.
Indications for Use
Indicated for quantitative measurement of glucose in fresh capillary whole blood from fingertips. Intended for self-testing by people with diabetes to monitor glucose control. Not for neonatal use, diagnosis, or screening of diabetes. Contraindicated for patients who are dehydrated, hypotensive, in shock, critically ill, or in a hyperosmolar state.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
- U-RIGHT TD-4279A Blood Glucose Monitoring System (k101509)
Reference Devices
- Glucose Control Solution (K032985)
Related Devices
- K072489 — REVOLUTION TD-4229 BLOOD GLUCOSE MONITORING SYSTEM · Taidoc Technology Corporation · Sep 20, 2007
- K062235 — EASY CHECK TD-4209 BLOOD GLUCOSE MONITORING SYSTEM; CLEVER CHECK TD-4222, TD-4225, TD-4226 BLOOD GLUCOSE MONITORING SYST · Taidoc Technology Corporation · Sep 19, 2006
- K071493 — CLEVER CHEK TD-4209 BLOOD GLUCOSE MONITORING SYSTEM, MODEL TD-4209, TD-4222, TD-4225 · Taidoc Technology Corporation · Oct 26, 2007
- K070239 — MAXIMED EXICHEK TD-4224 BLOOD GLUCOSE MONITORING SYSTEM · Exir Pharmaceutical Co. · May 25, 2007
- K082121 — EASYMAX SELF MONITORING GLUCOSE TEST SYSTEM, MODEL # EPS08005 · Eps Bio Technology Corp. · Sep 17, 2008
Submission Summary (Full Text)
{0}
1
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k113307
B. Purpose for Submission:
New Device
C. Measurand:
Capillary whole blood glucose
D. Type of Test:
Quantitative, Amperometric method, Glucose dehydrogenase (GDH-FAD)
E. Applicant:
HMD BioMedical Inc.
F. Proprietary and Established Names:
For single patient use:
GoodLife AC-300 Blood Glucose Monitoring System
GoodLife AC-301 Blood Glucose Monitoring System
GoodLife AC-302 Blood Glucose Monitoring System
GoodLife AC-303 Blood Glucose Monitoring System
GoodLife AC-304 Blood Glucose Monitoring System
GoodLife AC-305 Blood Glucose Monitoring System
For multiple patient use:
{1}
GoodLife AC-300 Professional Blood Glucose Monitoring System
GoodLife AC-301 Professional Blood Glucose Monitoring System
GoodLife AC-302 Professional Blood Glucose Monitoring System
GoodLife AC-303 Professional Blood Glucose Monitoring System
GoodLife AC-304 Professional Blood Glucose Monitoring System
GoodLife AC-305 Professional Blood Glucose Monitoring System
## G. Regulatory Information:
| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| LFR – glucose dehydrogenase, glucose | Class II | 21 CFR § 862.1345 | 75- Chemistry |
| NBW – system, test, blood glucose, over the counter | Class II | 21 CFR § 862.1345 | 75- Chemistry |
| JJX – Single Analyte control | Class I, reserved | 21 CFR § 862.1660 | 75 – Chemistry |
## H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indication(s) for use:
## GoodLife AC-300 Blood Glucose Monitoring System
The GoodLife AC-300 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-300 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-300 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-300 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
2
{2}
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-300 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-300 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-301 Blood Glucose Monitoring System
The GoodLife AC-301 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-301 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-301 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-301 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-301 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-301 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-302 Blood Glucose Monitoring System
The GoodLife AC-302 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-302 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-302 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-302 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-302 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh
3
{3}
capillary whole blood samples drawn from the fingertips only.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-302 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-303 Blood Glucose Monitoring System
The GoodLife AC-303 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-303 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-303 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-303 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-303 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-303 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-304 Blood Glucose Monitoring System
The GoodLife AC-304 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-304 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-304 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-304 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-304 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only.
4
{4}
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-304 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-305 Blood Glucose Monitoring System
The GoodLife AC-305 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood sample drawn from the fingertips only. The GoodLife AC-305 Blood Glucose Monitoring System is intended to be used by a single patient and should not be used for testing multiple patients.
The GoodLife AC-305 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-305 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use.
The GoodLife AC Blood Glucose Test Strips are for use with the GoodLife AC-305 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-305 Blood Glucose Meter and GoodLife AC Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-300 Professional Blood Glucose Monitoring System
The GoodLife AC-300 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-300 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-300 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-300 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
The GoodLife AC Professional Blood Glucose Test Strip are for use with the GoodLife AC-300 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
5
{5}
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-300 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-301 Professional Blood Glucose Monitoring System
The GoodLife AC-301 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-301 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-301 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-301 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
The GoodLife AC Professional Blood Glucose Test Strip are for use with the GoodLife AC-301 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-301 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-302 Professional Blood Glucose Monitoring System
The GoodLife AC-302 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-302 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-302 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-302 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
The GoodLife AC Professional Blood Glucose Test Strip are for use with the
{6}
GoodLife AC-302 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-302 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-303 Professional Blood Glucose Monitoring System
The GoodLife AC-303 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-303 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-303 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-303 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
The GoodLife AC Professional Blood Glucose Test Strip are for use with the GoodLife AC-303 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-303 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-304 Professional Blood Glucose Monitoring System
The GoodLife AC-304 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-304 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-304 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-304 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
7
{7}
The GoodLife AC Professional Blood Glucose Test Strip are for use with the GoodLife AC-304 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-304 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## GoodLife AC-305 Professional Blood Glucose Monitoring System
The GoodLife AC-305 Professional Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips only. The GoodLife AC-305 Professional Blood Glucose Monitoring System is intended to be used for testing multiple patients by a health care professional in a clinical setting.
The GoodLife AC-305 Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) by a health care professional in healthcare facilities as an aid to monitor the effectiveness of diabetes control. The GoodLife AC-305 Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. This system should only be used with single-use, auto-disabling lancing devices.
The GoodLife AC Professional Blood Glucose Test Strip are for use with the GoodLife AC-305 Professional Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips.
The GoodLife Glucose Control Solutions are for use with the GoodLife AC-305 Professional Blood Glucose Meter and GoodLife AC Professional Blood Glucose Test Strips to check that the meter and test strips are working together properly and that the test is performing correctly.
## 3. Special conditions for use statement(s):
For over-the-counter and prescription use
- Not intended for use on neonates
- Not for diagnosis of or screening for diabetes mellitus
- Not to be used for patients who are dehydrated, hypotensive, in shock, critically ill or in a hyperosmolar state
- Single-patient use systems are single-patient use only and should not be shared
- Multiple-patient use must be disinfected between use following labeling recommendations
- Multiple patient use systems should only use single use, auto disabling
{8}
lancing devices.
# 4. Special instrument requirements:
The GL GoodLife AC Series Blood Glucose Meters (Models: AC-300, AC-301, AC-302, AC-303, AC-304, AC-305) for single-patient use and the GL GoodLife AC Series Professional Blood Glucose Meters (Models: AC-300M - AC-301M, AC-302M, AC-303M, AC-304M, AC-305M) for multiple-patient use.
# I. Device Description:
The GL GoodLife Blood Glucose Monitoring System Series (Models: AC-300, AC-301, AC-302, AC-303, AC-304, AC-305) and the GL GoodLife Professional Blood Glucose Monitoring System Series (Models: AC-300M, AC-301M, AC-302M, AC-303M, AC-304M, AC-305M) consists of the following components: a glucose meter, glucose test strips and check strips, two (2) levels of glucose control solutions (Level I and Level II), and instructions for use. Each test strip contains $1.5\mathrm{U}$ of glucose dehydrogenase (FAD) obtained from Aspergillus oryzae, $0.08\mathrm{mg}$ of potassium ferricyanide, and 0.07 of non-reactive (excipient) ingredients.
1. Predicate device name(s):
U-RIGHT TD-4279A Blood Glucose Monitoring System
2. Predicate K number(s):
k101509
3. Comparison with predicate:
| Similarities and Differences of the Blood Glucose System | | |
| --- | --- | --- |
| Item | U-RIGHT TD-4279A Blood Glucose Monitoring System (predicate device), k101509 | GL GoodLife and GL GoodLife Professional Blood Glucose Monitoring Systems (candidate devices) |
| Intended Use/Indications for Use | It is designed to quantitatively measure the concentration of glucose in fresh capillary whole blood. | Same |
| Setting | For single and multiple patient use | GL GoodLife for single GL GoodLife Professional for multiple |
| Detection method | Amperometry | Same |
{9}
| Enzyme | Glucose dehydrogenase-FAD | Same |
| --- | --- | --- |
| Calibration Coding | Autocoding | Coding function is combined in each test strip. |
| Power supply | Two (2) 1.5V AAA size alkaline batteries | One (1) 3V lithium battery |
| Memory | Meter stores the most recent blood glucose test results | Memory capacity is 999 entries |
| Test range | 20 - 600 mg/dL | 20 – 600 mg/dL |
| Hematocrit range | 20 – 70% | 30-55% |
| Sample type | Capillary and venous whole blood | Capillary whole blood |
| Sample sites | Fingertip | Same |
| Sample volume | 1.1 μL | 0.5 μL |
| Sample test time | 7 seconds | 5 seconds |
# K. Standard/Guidance Document Referenced (if applicable):
(1) ISO 15197:2003 In vitro diagnostic test systems - Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus
(2) IEC 60601-1:1988 + A1:1991 + A2:1995 Medical electrical equipment - Part 1: General requirements for safety
(3) IEC 60601-1-2:2007 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility- Requirements and tests
(4) CLSI/NCCLS EP05-A2: Evaluation of Precision Performance of Quantitative Measurement Methods
(5) CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement.
(6) CLSI EP07-A2: Interference Testing in Clinical Chemistry
(7) CLSI/NCCLS EP09-A2: Method Comparison and Bias Estimation Using Patient Samples
(8) FDA Guidance: Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, May 11, 2005
# L. Test Principle:
The GL GoodLife and GL GoodLife Professional Blood Glucose Monitoring Systems use Glucose dehydrogenase-FAD enzyme chemistry as the standard dry reagent assay for glucose in whole blood. A glucose dehydrogenase sensor based on the carbon electrode adopting the amperometric assay utilizes the enzyme glucose dehydrogenase to catalyze the formation of gluconolactone for the oxidation of glucose. As a result of this reaction, two electrons are produced forming an electrical current that is proportional to the concentration of glucose in the sample.
{10}
M. Performance Characteristics (if/when applicable):
The GoodLife AC-300 Blood Glucose Meter was chosen as the representative meter for the twelve meter models in the single and multiple patient use meter model series. The AC-300 meter was used for all performance studies as the twelve meter models are identical; the only differences between each meter are the shape of the meter and the size and shape of the buttons; however the functions of all twelve meters are identical. The GL GoodLife and GL GoodLife Professional Blood Glucose Monitoring Systems utilizes test strips under two names: GL GoodLife AC Blood Glucose Test Strips (for models: AC-300, AC-301, AC-302, AC-303, AC-304, AC-305) and GL GoodLife AC Professional Blood Glucose Test Strips (for models: AC-300 professional, AC-301 professional, AC-302 professional, AC-303 professional, AC-304 professional, AC- 305 professional glucose meters)
1. Analytical performance:
a. Precision/Reproducibility:
Within-run precision was measured by using EDTA venous whole blood as the anti-coagulant at six different glucose concentrations. Each blood sample was adjusted to a hematocrit level ranging from 30-55% and verified by an automated method. Each sample was tested on 3 lots of test strips on 30 meters (10 meters per test strip lot). Ten replicates were tested per meter, test strip lot, and glucose concentration, (N=100 per test strip). Results are summarized below:
| Glucose Level (mg/dL) | Strip Lot | YSI (mg/dL) | Mean (mg/dL) | SD (mg/dL) | %CV |
| --- | --- | --- | --- | --- | --- |
| 30 - 50mg/dL | 1 | 42 | 45.0 | 1.8 | 4.0 |
| | 2 | 42 | 43.0 | 1.8 | 4.2 |
| | 3 | 43 | 43.0 | 1.9 | 4.3 |
| 51 - 110 mg/dL | 1 | 104 | 104.2 | 3.5 | 3.4 |
| | 2 | 104 | 103.9 | 3.3 | 3.2 |
| | 3 | 109 | 103.6 | 3.4 | 3.3 |
| 111 - 150 mg/dL | 1 | 119 | 121.8 | 5.6 | 4.6 |
| | 2 | 119 | 123.1 | 5.2 | 4.2 |
| | 3 | 122 | 122.2 | 5.4 | 4.5 |
| 151 - 250 mg/dL | 1 | 199 | 193.7 | 7.1 | 3.7 |
| | 2 | 199 | 194.5 | 7.5 | 3.9 |
| | 3 | 187 | 192.2 | 7.3 | 3.8 |
| 251 - 400 mg/dL | 1 | 297 | 305.4 | 8.7 | 2.8 |
| | 2 | 297 | 303.8 | 9.1 | 3.0 |
| | 3 | 288 | 301.9 | 8.1 | 2.7 |
| 401 - 600 | 1 | 558 | 581.3 | 15.7 | 2.7 |
{11}
Between-day precision was measured by reading three different control materials on 3 lots of test strips, using 10 test strips on 10 meters (1 strip per meter), over 10 days (N=100 per test strip). Results are summarized below:
| Control Level | Strip Lot | YSI (mg/dL) | Mean (mg/dL) | SD (mg/dL) | % CV |
| --- | --- | --- | --- | --- | --- |
| Level I | 1 | 44 | 45.4 | 2.2 | 4.8 |
| | 2 | 44 | 46.5 | 2.2 | 4.8 |
| | 3 | 44 | 45.1 | 2.1 | 4.6 |
| Level II | 1 | 108 | 115.7 | 4.3 | 3.7 |
| | 2 | 108 | 115.0 | 4.9 | 4.3 |
| | 3 | 108 | 114.7 | 4.8 | 4.1 |
| Level III | 1 | 302 | 311.6 | 10.3 | 3.3 |
| | 2 | 302 | 313.3 | 11.3 | 3.6 |
| | 3 | 302 | 311.7 | 15.1 | 4.8 |
# b. Linearity/assay reportable range:
The linearity study was designed following CLSI EP6-A guideline. Venous (EDTA) whole blood samples were drawn and spiked to target analyte levels. Eight (8) target levels were prepared with glucose stock solutions to glucose concentrations ranging from $<20\mathrm{mg/dL}$ to $>600\mathrm{mg/dL}$ (18, 40, 107, 119, 184, 276, 476, 615 mg/dL). A total of 480 strips from 3 strip lots were used for this study. Each sample was tested on 160 strips per lot (3 lots of test strips) using two meters. All samples were also tested on a YSI analyzer to generate the expected values. The observed values were plotted against an average of the expected values and an appropriate line fitted by standard linear regression was generated with results summarized below:
| Strip Lot | Slope | Intercept | R2 |
| --- | --- | --- | --- |
| 1 | 1.01 | 2.51 | 0.997 |
| 2 | 0.99 | 3.23 | 0.995 |
| 3 | 1.01 | 0.36 | 0.997 |
| Combined | 1.01 | 2.03 | 0.996 |
The sponsor's claimed measurement range for glucose is $20 - 600\mathrm{mg / dL}$
{12}
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
The GL GoodLife and GL GoodLife Professional Glucose Monitoring Systems are traceable to the NIST SRM 917a reference material.
Control solutions previously cleared: See k032985 for traceability, stability, and expected value information.
Test Strip Stability:
Shelf Life: GL GoodLife AC blood glucose test strips were stored at (4°C±2°C and 45% ±5%RH), (30°C ±2°C and 65% ±5%RH), and (42°C ±2°C and 75% ±5%RH). For this study, one lot (28 vials, 25 strips per vial) of test strips were used and were divided into 3 groups stored at temp/humidity combinations specified above for real time shelf life stability testing. Glucose values obtained using the GL GoodLife meter were compared to glucose values obtained using YSI reference method at 1, 3, 6, 9, 12, 18, and 24 months. The sponsor claims shelf life of 24 months when stored at 50-104 °F (10-40 °C). Testing protocols and acceptance criteria were reviewed and found to be acceptable.
Open Vial test strip stability: 156 vials (25 strips per vial) of GL GoodLife AC blood glucose test strips from one (1) lot were divided into 3 groups and stored at (4°C±2°C and 45% ±5%RH), (30°C ±2°C and 65% ±5%RH), and (42°C ±2°C and 75% ±5%RH). Eight (8) different blood glucose concentrations were tested 10 times using one meter. Glucose values obtained using the GL GoodLife meter were compared to glucose values obtained using YSI reference method at 1, 3, 6, 9, 12, and 13 weeks. The sponsor claims open vial stability of 90 days after first opening when stored at 50-104 °F (10-40 °C). Testing protocols and acceptance criteria were reviewed and found to be acceptable.
d. Detection limit:
See linearity study above.
e. Analytical specificity:
Interference study was designed according to CLSI EP7-A2 guideline. Common endogenous and exogenous substances were evaluated for interference by first spiking venous whole blood (collected in tubes containing EDTA) to two levels of glucose concentrations (60-70 mg/dL and 250-350 mg/dL) and then dividing each level to a control and test aliquot. The endogenous and exogenous substances to be evaluated were then added to the
13
{13}
test aliquot. Each interfering substance was evaluated at 4 concentrations on 3 lots of test strips. Bias was calculated as the difference between the test and control concentration groups. The following tables show the test concentrations for each potential interfering substance:
| Substance | Therapeutic/ Physiological Levels | Highest concentration without interference (mg/dL) |
| --- | --- | --- |
| Acetaminophen1 | 1.00-3.00 | 20 |
| Ascorbic acid1 | 0.40-2.00 | 3 |
| Bilirubin1 | 0.29-1.23 | 40 |
| Cholesterol1 | 150-250 | 500 |
| Creatinine1 | 0.60-1.30 | 10 |
| Dopamine1 | 0.03 | 20 |
| EDTA1 | N/A | 0.1 |
| Ephedrine2 | 0.005-0.01 | 10 |
| Galactose1 | 0.00-5.00 | 100 |
| Gentisic Acid1 | 0.20-0.60 | 2 |
| Glutathione1 | 24.25-32.24 | 60 |
| Heparin1 | 350-1000U/L | 3000U/L |
| Ibuprofen1 | 1.00-7.00 | 50 |
| Icodextrin2 | 500 | 600 |
| Lactose3 | 0.00-0.50 | 20 |
| L-dopa2 | 0.02-0.28 | 0.8 |
| Maltose2 | 120 | 200 |
| Methyldopa1 | 0.10-0.75 | 1.6 |
| Salicyate1 | 9.94-29.95 | 50 |
| Tetracycline1 | 0.20-0.50 | 1.6 |
| Tolazamide2 | 3.00 | 6.25 |
| Tolbutamide1 | 5.40-10.80 | 64 |
| Triglycerides1 | 150-500 | 2000 |
| Urea1 | 6.60-85.80 | 600 |
| Uric acid1 | 2.52-8.00 | 9 |
| Xylose2 | 57 | 50 |
| hemoglobin1 | 100-200 | 450 |
| ethanol1 | 100-200 | 400 |
| fructose1 | 1.01-5.99 | 40 |
| Mannitol4 | 1000 | 1200 |
| Sorbitol3 | 0.044 | 10 |
{14}
Reference:
1. The CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline- Second Edition
2. k110894 CONTOUR NEXT LINK Wireless BGMS, Bayer Healthcare LLC, Diabetes Care
3. k111890 FORA Diamond Prima & Mini BGMS, Taidoc Technology Corporation
4. k101509 U-RIGHT TD-4279A BGMS, Taidoc Technology Corporation
Lipemic effects: Elevated triglycerides up to $2000\mathrm{mg / dL}$ do not significantly affect the results
Significant $(> + / - 10\%)$ bias) interference was noted for xylose at concentrations $>50~\mathrm{mg / dL}$
f. Assay cut-off:
Not applicable.
# 2. Comparison studies:
a. Method comparison with predicate device:
System accuracy study:
This study was designed following ISO 15197:2003(E) using 100 fresh capillary blood samples collected from participants from a diabetic clinic and measured using two AC-300 meters. Fingerstick samples were collected by two trained technicians over a 10 day period. Venous blood was also collected and measured on the YSI analyzer. Pooled and altered samples were used for glucose values less than $50\mathrm{mg / dL}$ and greater than $400\mathrm{mg / dL}$ ; each sample allowed to glycolyze or spiked with a stock glucose solution to the desired glucose level. Results obtained using the AC-300 meters were compared to results obtained using the YSI 2300 (reference method). The range of samples tested was $31 - 453\mathrm{mg / dL}$ . System accuracy results are summarized below:
Lot 1:
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ with AC-300
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 7/18 (39%) | 16/18 (89%) | 18/18 (100%) |
System accuracy results for glucose concentrations $\geq 75\mathrm{mg / dL}$ with AC-300
| Within ± 5% | Within ± 10% | Within ± 15% | Within ± 20% |
| --- | --- | --- | --- |
| 29/82 (35%) | 62/82 (76%) | 78/82 (95%) | 79/82 (96%) |
{15}
Linear regression between AC-300 and YSI
| Accuracy of AC-300 compared to YSI using capillary whole blood | N=100 Y=0.92x+6.54 R²=0.9752 Sy.x=16.08 Range: 35-453 mg/dL |
| --- | --- |
Lot 2:
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ with AC-300
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 8/18 (44%) | 17/18 (94%) | 18/18 (100%) |
System accuracy results for glucose concentrations $\geq 75\mathrm{mg / dL}$ with AC-300
| Within ± 5% | Within ± 10% | Within ± 15% | Within ± 20% |
| --- | --- | --- | --- |
| 43/82 (52%) | 68/82 (83%) | 76/82 (93%) | 80/82 (98%) |
Linear regression between AC-300 and YSI
| Accuracy of AC-300 compared to YSI using capillary whole blood | N=100 Y=0.95x+6.51 R²=0.9815 Sy.x=13.87 Range: 35-453 mg/dL |
| --- | --- |
Lot 3:
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ with AC-300
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 8/19 (42%) | 18/19 (95%) | 19/19 (100%) |
System accuracy results for glucose concentrations $\geq 75\mathrm{mg / dL}$ with AC-300
| Within ± 5% | Within ± 10% | Within ± 15% | Within ± 20% |
| --- | --- | --- | --- |
| 43/81 (53%) | 70/81 (86%) | 78/81 (96%) | 79/81 (98%) |
Linear regression between AC-300 and YSI
| Accuracy of AC-300 compared to YSI using capillary whole blood | N=100 Y=0.92x+6.95 R²=0.9826 Sy.x=12.59 Range: 31-444 mg/dL |
| --- | --- |
{16}
b. Matrix comparison:
None. Only capillary whole blood samples are acceptable matrix.
# 3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Lay user performance study:
This study was conducted following the ISO Standard 15197 and compared layuser self-test fingerstick to the YSI method. This study was performed at three sites (two hospitals and a diabetes clinic) and using capillary blood samples collected by 150 subjects. The glucose sample ranges were from $56 - 388\mathrm{mg / dL}$ . The results of this study, linearity, and method comparison support the claimed measuring range of $20 - 600\mathrm{mg / dL}$ .
Regressions between Lay user's fingerstick results and the YSI method/Technician result and the YSI method:
| Tester | Linear Regression | R | N |
| --- | --- | --- | --- |
| Layperson | Y=0.99x + 9.35 | 0.97 | 150 |
| Technician | Y=0.95x +3.52 | 0.99 | 150 |
Based on the ISO Standard 15197 document, how well lay-users tested themselves (using fingertip) as compared with the YSI method is shown in the following table:
| Glucose concentration < 75 mg/dL | | | | |
| --- | --- | --- | --- | --- |
| Within ± 5 mg/dL | | Within ± 10 mg/dL | | Within ± 15 mg/dL |
| 3/3(100%) | | 3/3(100%) | | 3/3(100%) |
| Glucose concentration 75 mg/dL | | | | |
| Within ± 5% | Within ± 10% | | Within ± 15% | Within ± 20% |
| 56/147(38%) | 92/147(63%) | | 125/147(85%) | 141/147(96%) |
{17}
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
For people without diabetes:
The normal blood glucose range for people without diabetes:
Fasting and before meals: Less than 100 mg/dL
2 hours after meals: Less than 140 mg/dL
American Diabetes Association Position Statement, Diabetes Care Vol.34
(Suppl.1) p.S13 (2011)
N. Instrument Name:
GL GoodLife Blood Glucose Meters (Models: AC-300, AC-301, AC-302, AC-303, AC-304, AC-305) for single patient use and The GL GoodLife Professional Blood Glucose Meters (Models: AC-300M, AC-301M, AC-302M, AC-303M, AC-304M, AC-305M) for multiple patient use.
O. System Descriptions:
1. Modes of Operation:
Each test strip is single use and requires a sample volume of 0.5 uL.
Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?
Yes ☐ X ☐ or No ☐
Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?
Yes ☐ or No ☐ X ☐
2. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:
Yes ☐ X ☐ or No ☐
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied
18
{18}
directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
The glucose test is intended to be used with capillary whole blood from the fingertip only. The whole blood sample is applied directly to the test strip by capillary action.
5. Calibration:
There is no calibration required for the GL GoodLife meter by the user. The meter is plasma-calibrated.
6. Quality Control:
GL Glucose control solutions at two different concentrations (Levels 1 and 2) can be run with this device. The meter has an algorithm to automatically recognize the control solutions to prevent control results from being stored in the internal memory as patient result. Recommendations on when to test the control materials are provided in the labeling. The control solution readings are not included in the average of the patient results. An acceptable range for each control level is printed on the control solutions vial label. The user is cautioned not to use the meter if the control result falls outside these ranges.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
1. Altitude Study:
This study was conducted at three sites to evaluate the effect of altitude on the GL GoodLife BGMS. One lot of test strips was tested on 4 meters. Eight different venous whole blood (EDTA) glucose concentrations were evaluated on each meter in replicates of five at each site and at altitudes of 0.33 feet, 5,741 feet, and 8,800 feet. The samples tested spanned the device measuring range. These blood samples were evaluated using both the GL GoodLife blood glucose meter and an YSI glucose analyzer. Each test strip glucose value was compared to the YSI method and then analyzed as a percent bias. The glucose values obtained using the GL GoodLife glucose meter had acceptable biases compared to YSI to support use at altitudes up to 8,800 feet. The results demonstrate acceptable bias to YSI to support the claims in the labeling that altitudes up to 8,800 feet have no significant effect on blood glucose measurements from the GL GoodLife and GL GoodLife Professional Blood Glucose Monitoring Systems.
19
{19}
20
2. Hematocrit Study:
The sponsor performed hematocrit studies using seven different hematocrit (25, 30, 35, 40, 45, 55, 60%) levels distributed across the glucose measuring range (20 – 600 mg/dL). Each glucose concentration/hematocrit level was tested in replicates of six (6) using one (1) meter. The results support the sponsor’s hematocrit claim of 30% - 55%.
3. Temperature and Relative Humidity Study:
In this study, two meters were evaluated at 10 combined temperature and relative humidity conditions (8°C, 10°C, 25°C, 40°C, 42°C with 15% RH and (8°C, 10°C, 25°C, 40°C, 42°C with 85%RH). Each sample was compared to the YSI reference method. The meters and test strips were at each temperature/humidity combination for at least 30 minutes prior to glucose concentration testing. Eight venous whole blood samples were adjusted to the following glucose concentration levels: (<20 mg/dL, 20-50 mg/dL, 51-110 mg/dL, 111-150 mg/dL, 151-250 mg/dL, 251-400 mg/dL, 401-600 mg/dL, and >600 mg/dL) and were evaluated on each meter in replicates of five (2 meters x 5 replicates). The results demonstrate that accurate readings can be obtained after exposure to temperatures ranging from 50 ~ 104°F (10 ~ 40°C) and relative humidity conditions at 15 and 85%.
4. EMC Electromagnetic Compatibility and Electrical Safety verification testing of the GL GoodLife Blood Glucose Monitoring System was performed following the requirements of ISO 15197:2003 (E). A signed technical compliance statement was provided demonstrating that EMC testing was performed following standards listed in the test report.
5. Sample volume study:
HMD Biomedical performed a sample volume study to demonstrate that 0.5μL of whole blood is sufficient volume for the GL GoodLife AC-300 Blood Glucose Monitoring System. For this study, whole blood sample volumes ranging from 0.3μL – 0.7 μL were evaluated using three different lots of test strips. The blood glucose sample results collected using the GL GoodLife Meter were compared with glucose values obtained with the YSI reference method and supported the minimum sample volume claim of 0.5μL.
6. Infection control:
The device (GL GoodLife and GL GoodLife Professional Blood Glucose Monitoring systems) is intended for single (AC-300 - 305) or multiple patient use (AC-300M - 305M). Clorox Commercial Solutions® Clorox Germicidal Wipes (EPA Reg No.67619-12) were validated by virucide efficacy testing using Hepatitis B surface antigen (HBsAg) using materials from the meter. Robustness studies were also performed demonstrating that there was no change in device performance or in the external materials of the meters after 520
{20}
cleaning and disinfection cycles to simulate single-patient use or after 18,250 cleaning and disinfecting cycles to simulate 5 years of multiple patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.
7. Readability: A Flesch-Kincaid analysis was conducted and the resulting grade level at which the device labeling is written is as follows:
| Labeling | Flesch-Kincaid Grade Level Score |
| --- | --- |
| User's Manual | 7.9 |
| Test Strip Insert | 7.8 |
| Control Solution Insert | 7.6 |
# Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
# R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
